文献速递肝病消化道肿瘤与早癌

循环骨桥蛋白水平升高与胆管癌切除术后生存不良相关

Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
PubMed 文献 · J Hepatol · 2017-06-29

该研究分析了人和鼠胆管癌(CCA)肿瘤样本中骨桥蛋白的表达,并用酶联免疫吸附法测定了107例接受择期肿瘤切除术的CCA患者及55名健康对照者的血清骨桥蛋白浓度,结果与临床数据相关联。CCA患者血清骨桥蛋白水平较健康对照者和原发性硬化性胆管炎患者升高,且术前和术后骨桥蛋白升高与术后生存不良显著相关。血清骨桥蛋白浓度是可切除CCA患者有前景的预后生物标志物。

要点

  • CCA患者血清骨桥蛋白水平高于健康对照者和原发性硬化性胆管炎患者。
  • 术前和术后骨桥蛋白升高均与术后生存不良显著相关。
  • 血清骨桥蛋白或有助于指导术前治疗决策和识别能从扩大肝切除术中获益的患者。

核心结论

  • 血清骨桥蛋白浓度是可切除CCA患者有前景的预后生物标志物,可能有助于指导术前治疗决策并识别特别受益于扩大肝手术的患者。

研究设计与样本

  • 分析人和鼠CCA肿瘤样本中骨桥蛋白表达水平,采用半定量逆转录聚合酶链反应和免疫组织化学。
  • 用酶联免疫吸附法测定107例接受择期肿瘤切除术的CCA患者及55名健康对照者的血清骨桥蛋白浓度,结果与临床数据相关联。

主要发现

  • 与CCA肿瘤细胞和肿瘤间质中骨桥蛋白上调相一致,CCA患者血清骨桥蛋白水平较健康对照者和原发性硬化性胆管炎患者升高。
  • 术前和术后骨桥蛋白升高均与术后生存不良显著相关。

临床怎么用

  • 作者认为血清骨桥蛋白浓度是可切除CCA患者有前景的预后生物标志物,可能有助于指导术前治疗决策并识别特别受益于扩大肝手术的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cholangiocarcinoma (CCA) represents a primary hepatic malignancy with incidence and mortality rising globally. Surgical treatment has remained the only potentially curative treatment option, but it is still unclear which patients benefit most from extended liver surgery, highlighting the need for new pre-operative stratification strategies. Osteopontin is a secreted extracellular glyco-phosphoprotein that has been associated with inflammation, metabolic disorders and cancer. Here, we examined the potential of circulating osteopontin serum levels as a diagnostic or prognostic biomarker in patients with CCA undergoing extended liver surgery. METHODS: Osteopontin expression levels were analysed in human and murine CCA tumour samples, using semi-quantitative reverse transcriptase PCR and immunohistochemistry. Osteopontin serum concentrations were measured by enzyme-linked immunosorbent assay in 107 patients with CCA undergoing elective tumour resection as well as 55 healthy controls. Results were correlated with clinical data. RESULTS: Correlating with an upregulation in CCA tumour cells and the tumour stroma, serum levels of osteopontin were elevated in patients with cholangiocarcinoma compared to healthy controls and patients with primary sclerosing cholangitis. Importantly, pre- and postoperative elevations of osteopontin showed a striking association with poor postoperative survival. CONCLUSIONS: Serum osteopontin concentrations represent a promising prognostic biomarker in patients resectable CCA which could help to guide preoperative treatment decisions and to identify patients that will particularly benefit from extended liver surgery. Lay summary: Extended liver surgery is the only potentially curative treatment for patients with cholangiocarcinoma (CCA/biliary cancer), but it is currently unclear which patients benefit most from surgery. Detecting serum levels of osteopontin - a specific secreted glycoprotein involved in multiple human diseases - in CCA patients might help to identify those patients that particularly benefit from tumour resection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Loosen SH, Roderburg C, Kauertz KL, et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatol. 2017. PMID: 28668580. doi:10.1016/j.jhep.2017.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。